Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) flaunted slowness of -1.02% at $21.41, before settling in for the price of $21.63 at the close. Taking a more long-term approach, ARWR posted a 52-week range of $17.05-$39.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 21.04%. Meanwhile, its Annual Earning per share during the time was -24.19%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -137.85%. This publicly-traded company’s shares outstanding now amounts to $124.31 million, simultaneously with a float of $118.50 million. The organization now has a market capitalization sitting at $2.66 billion. At the time of writing, stock’s 50-day Moving Average stood at $20.19, while the 200-day Moving Average is $24.98.
Arrowhead Pharmaceuticals Inc (ARWR) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Arrowhead Pharmaceuticals Inc industry. Arrowhead Pharmaceuticals Inc’s current insider ownership accounts for 4.68%, in contrast to 75.54% institutional ownership. According to the most recent insider trade that took place on Jul 02 ’24, this organization’s Chief Commercial Officer sold 9,394 shares at the rate of 25.28, making the entire transaction reach 237,480 in total value, affecting insider ownership by 127,107. Preceding that transaction, on May 02 ’24, Company’s Director sold 1,799 for 23.31, making the whole transaction’s value amount to 41,935. This particular insider is now the holder of 30,205 in total.
Arrowhead Pharmaceuticals Inc (ARWR) Earnings and Revenue Records
Arrowhead Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -137.85% and is forecasted to reach -4.36 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 7.33% through the next 5 years, which can be compared against the -24.19% growth it accomplished over the previous five years trading on the market.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Let’s observe the current performance indicators for Arrowhead Pharmaceuticals Inc (ARWR). It’s Quick Ratio in the last reported quarter now stands at 4.65. The Stock has managed to achieve an average true range (ATR) of 0.81. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 135.45.
In the same vein, ARWR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.65, a figure that is expected to reach -0.97 in the next quarter, and analysts are predicting that it will be -4.36 at the market close of one year from today.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Now, what If we examine the latest scores posted by [Arrowhead Pharmaceuticals Inc, ARWR]. During the last 5-days, its volume was lower the volume of 1.2 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 69.87% While, its Average True Range was 0.79.
Raw Stochastic average of Arrowhead Pharmaceuticals Inc (ARWR) in the period of the previous 100 days is set at 32.63%, which indicates a major fall in contrast to 66.77% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 29.10% that was lower than 44.82% volatility it exhibited in the past 100-days period.
